American Society of Clinical Oncology (ASCO) 2024 Annual Meeting is being held Friday, May 31st through Tuesday, June 4th, with numerous scheduled sessions related to minimal residual disease in colorectal cancer.
Highlighted Sessions and Posters
- Use of MRD-Guided Strategies to Optimize Therapeutic Interventions
- Circulating Biomarkers: Who, What, Where, When, and Why?
- Gastrointestinal Cancer—Colorectal and Anal Abstracts and Posters
- Clinical validation of a novel circulating tumor DNA methylation assay for predicting recurrence of colorectal cancer in patients with curative-intent surgery by monitoring minimal residual disease.
- A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.
- Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan.
- Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
- Individualized tumor-informed circulating tumor DNA analysis for molecular residual disease detection in predicting recurrence and efficacy of adjuvant chemotherapy in colorectal cancer.
- Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): Implications from PRECISION study.
